Denali Therapeutics Inc. (DNLI): R&D Expense
$418.78M
Year ended 2025-12-31
$400.72M
Trailing 12 months to 2026-06-30
+5.3%
3-year compound annual growth
+14.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $418.78M | +5.6% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $396.44M | -6.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $423.88M | +18.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $358.73M | +35.2% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $265.35M | +24.8% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $212.62M | +9.9% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $193.38M | +35.1% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $143.18M | +92.3% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $74.46M | -1.6% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $75.70M | n/a | 2019-03-12, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $418.78M | +5.6% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Amgen Inc (AMGN) | 2025-12-31 | $7.27B | +21.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $54.18M | +25.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $9.08M | +33.1% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $1.78B | -10.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $5.80B | -1.8% |
Compare DNLI, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗